1388129-63-2|Lonoctocog alfa|Lonoctocog alfa|-范德生物科技公司

Lonoctocog alfa

NMR下载 COA and HPLC MSDS下载
names：
Lonoctocog alfa
CAS号：
1388129-63-2
MDL Number：
MF(分子式)： MW(分子量)：
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
DBK502154-500mg	500mg		¥ 0.00	¥ 0.00		Get quote	- +	¥ 0.00
DBK502154-100mg	100mg		¥ 0.00	¥ 0.00		Get quote	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Lonoctocog alfa
英文别名	Lonoctocog alfa
CAS号	1388129-63-2
SMILES
Inchi
InchiKey
分子式 Formula
分子量 Molecular Weight
闪点 FP	NA
熔点 Melting point	NA
沸点 Boiling point	NA
Polarizability极化度
密度 Density	NA
蒸汽压 Vapor Pressure
溶解度Solubility
性状	NA
储藏条件 Storage conditions

Lonoctocog alfa使用注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害。
3.取样品的移液枪头需及时更换，必要时为避免交叉污染尽可能选择滤芯吸头。
4.称量药品时选用称量纸，并无风处取药和称量以免扬撒，试剂的容器使用前务必确保干净，并消毒。
5.取药品时尽量采用多个药勺分别使用，使用后清洗干净。
6.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染。
大规格定制：定制产品请将信息发送至sales@bio-fount.com。
Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

产品说明	The primary psychoactive component of Cannabis, delta 9-tetrahydrocannabinol (Δ9-THC), demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors. This activity results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. In contrast to THC's weak agonist activity, CBD has been shown to act as a negative allosteric modulator of the cannabinoid CB1 receptor, the most abundant G-Protein Coupled Receptor (GPCR) in the body2. Allosteric regulation is achieved through the modulation of receptor activity on a functionally distinct site from the agonist or antagonist binding site. The negative allosteric modulatory effects of CBD are therapeutically important as direct agonists are limited by their psychomimetic effects while direct antagonists are limited by their depressant effects2.There is further evidence that CBD also activates 5-HT1A serotonergic and TRPV1–2 vanilloid receptors, antagonizes alpha-1 adrenergic and μ-opioid receptors, inhibits synaptosomal uptake of noradrenaline, dopamine, serotonin and gaminobutyric acid and cellular uptake of anandamide, acts on mitochondria Ca2 stores, blocks low-voltage-activated (T-type) Ca2 channels, stimulates activity of the inhibitory glycine-receptor, and inhibits activity of fatty amide hydrolase (FAAH)3,4.TargetActionsOrganismACannabinoid receptor 1Not AvailableHumansACannabinoid receptor 2Not AvailableHumansUG-protein coupled receptor 12inverse agonistHumansUGlycine receptor subunit alpha-1Not AvailableHumansUGlycine receptor (alpha-1/beta)Not AvailableHumansUGlycine receptor subunit alpha-3Not AvailableHumansUN-arachidonyl glycine receptorNot AvailableHumansUG-protein coupled receptor 55Not AvailableHumansU5-hydroxytryptamine receptor 1ANot AvailableHumansU5-hydroxytryptamine receptor 2ANot AvailableHumansUNeuronal acetylcholine receptor subunit alpha-7Not AvailableHumansUDelta-type opioid receptorNot AvailableHumansUMu-type opioid receptorNot AvailableHumansUPeroxisome proliferator-activated receptor gammaNot AvailableHumansUTransient receptor potential cation channel subfamily V member 1Not AvailableHumansUVoltage-dependent T-type calcium channel subunit alpha-1GNot AvailableHumansUVoltage-dependent T-type calcium channel subunit alpha-1HNot AvailableHumansUVoltage-dependent T-type calcium channel subunit alpha-1INot AvailableHumansUTransient receptor potential cation channel subfamily A member 1Not AvailableHumansUTransient receptor potential cation channel subfamily M member 8Not AvailableHumansUTransient receptor potential cation channel subfamily V member 2Not AvailableHumansUTransient receptor potential cation channel subfamily V member 3Not AvailableHumansUTransient receptor potential cation channel subfamily V member 4Not AvailableHumansUVoltage-dependent anion-selective channel protein 1Not AvailableHumansUProstaglandin G/H synthase 1inhibitorHumansUProstaglandin G/H synthase 2inhibitorHumansUAcetyl-CoA acetyltransferase, mitochondrialinhibitorHumansUSteroid 17-alpha-hydroxylase/17,20 lyaseinhibitorHumansU3-hydroxy-3-methylglutaryl-coenzyme A reductasestimulatorHumansUGlutathione reductase, mitochondrialstimulatorHumansUGlutathione peroxidase 1stimulatorHumansUIndoleamine 2,3-dioxygenase 1inhibitorHumansUArylalkylamine N-acetyltransferaseinhibitorHumansUCytochrome P450 1B1inhibitorHumansUCytochrome P450 3A5inhibitorHumansUCytochrome P450 2D6substrateinhibitorHumansUCytochrome P450 1A2inhibitorHumansUCytochrome P450 1A1inhibitorHumansUCytochrome P450 3A7inhibitorHumansUQuinone oxidoreductaseinhibitorHumansUCatalaseinhibitorHumansUFatty-acid amide hydrolase 1inhibitorinducerHumansUSuperoxide dismutase [Cu-Zn]inhibitorHumansUN-acylethanolamine-hydrolyzing acid amidaseinhibitorHumans
Introduction
Application1
Application2
Application3